Accessibility Menu
Immunotech Biopharm logo

Immunotech Biopharm(SEHK) 6978

Market CapHK$240.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-97%
5 Year-98%
1 Year-93%
1 Month+10%
HK$0.39
+0.00%
+0.00Today
Immunotech Biopharm last closing stock price
MetricPriceDate
Last closeHKD 0.392026-08-31
Immunotech Biopharm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%HKD 0.392026-08-24
1 month+9.86%HKD 0.362026-07-31
3 month-46.58%HKD 0.732026-06-02
Year to date-86.69%HKD 2.932025-12-31
1 year-92.6%HKD 5.272025-08-29
3 year-91.88%HKD 4.802023-08-31
5 year-97.59%HKD 16.162021-09-01
Since inception-97.26%HKD 14.232020-07-10

Immunotech Biopharm Financials at a Glance

Market Cap

HK$240.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥0.00

Net Income (TTM)

-CN¥392.39M

EPS (TTM)

-HK$0.34

P/E Ratio

-1.16

Dividend

HK$0.00

Beta (Volatility)

-0.14 (Low)

Price

HK$0.39

Volume

43,000

Open

HK$0.39

Previous Close

HK$0.39

Daily Range

HK$0.38 - HK$0.40

52-Week Range

HK$0.33 - HK$5.83

Estimated Earnings Date

Mar 19, 2027

6978 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunotech Biopharm

Immunotech Biopharm Ltd is a biopharmaceutical company focused on cellular immunotherapy, primarily targeting various cancers in China. The firm is advancing its flagship product, EAL, through clinical trials while exploring additional therapies for multiple cancer types.

Products and Services
  • EAL: A multi-target cellular immunotherapy in Phase II trials for liver cancer
  • 6B11-OCIK injection: Currently in Phase I trials for ovarian cancer
  • CAR-T-19 injection: Targeting B-cell acute lymphoblastic leukaemia
Growth Outlook
  • Ongoing Phase II trials for EAL may lead to market introduction
  • Expansion of research into therapies for lung, glioma, gastric, and colorectal cancers
  • Strong pipeline with multiple products in various stages of development
Financial Highlights
  • Recent quarterly net income of -99.99 million CNY, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) revenue remains at 0 CNY, indicating early-stage development
  • Cash and short-term investments totaled 154.63 million CNY as of the latest quarter
Immunotech Biopharm Ltd operates in a dynamic and competitive biotechnology sector, focusing on innovative cancer therapies. The company's commitment to research and development is evident in its substantial investments, which are crucial for advancing its product pipeline. Despite reporting no revenue, the ongoing clinical trials and research initiatives position the company for potential future growth. The financial data indicates a strong cash position, which may support continued development efforts. Investors may find the company's focus on cellular immunotherapy and its diverse pipeline of products appealing as the market for cancer treatments continues to expand.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

183

CEO

Jian Zhang

Headquarters

Beijing, BE, CN

6978 Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

345.69%

Return on Capital

-36.54%

Return on Assets

-35.20%

Earnings Yield

-86.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$240.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

617.50M

Volume

43.00K

Avg. Volume

299.97K

Financials (TTM)

Gross Profit

-CN¥49.84M

Operating Income

-CN¥326.74M

EBITDA

-CN¥227.21M

Operating Cash Flow

-CN¥232.83M

Capital Expenditure

-CN¥42.06M

Free Cash Flow

-CN¥274.89M

Cash & ST Invst.

CN¥65.93M

Total Debt

CN¥100.71M

Immunotech Biopharm Performance Analysis

Immunotech Biopharm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 0N/A
20232023-12-31CNY 0N/A
20242024-12-31CNY 0N/A
20252025-12-31CNY 0N/A
Immunotech Biopharm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A
Immunotech Biopharm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.66-13.3%
20232023-12-31CNY -0.660.0%
20242024-12-31CNY -0.36-45.2%
20252025-12-31CNY -0.4625.9%
Immunotech Biopharm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30-38.9%
Q42025-12-3132.0%
Q22026-06-3035.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥0.00

N/A

Gross Profit

-CN¥23.76M

N/A

Gross Margin

0.00%

N/A

Market Cap

HK$240.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.32M

N/A

Employees

183

N/A

Net Income

-CN¥68.90M

+25.5%

EBITDA

-CN¥45.96M

+45.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥65.93M

-54.6%

Total Debt

CN¥100.71M

-75.4%

Accounts Receivable

CN¥269.95K

N/A

Inventory

CN¥5.92M

-13.6%

Long Term Debt

CN¥71.43M

-26.5%

Short Term Debt

CN¥29.27M

-90.6%

Return on Assets

-35.20%

N/A

Return on Invested Capital

-4.94%

N/A

Free Cash Flow

-CN¥60.53M

-73950.9%

Operating Cash Flow

-CN¥55.32M

-73860.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 6978

What is the current price of Immunotech Biopharm?

Immunotech Biopharm is trading at HK$0.39 per share.

What is the 52-week range for Immunotech Biopharm?

Over the past 52 weeks, Immunotech Biopharm has traded between HK$0.33 and HK$5.83.

How much debt does Immunotech Biopharm have?

As of the most recent reporting period, Immunotech Biopharm reported total debt of CN¥490.37M.

How much cash does Immunotech Biopharm have on hand?

Immunotech Biopharm reported CN¥60.66M in cash and cash equivalents in its most recent financial results.

What is Immunotech Biopharm’s dividend yield?

Immunotech Biopharm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services